Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2018
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 02 Dec 2018 Results of post-hoc analysis determining the effect of adjunctive brexpiprazole using pooled data from six randomized studies (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT00797966, NCT01052077) published in the International Journal of Neuropsychopharmacology
- 16 May 2011 Primary endpoint, Montgomery Asberg Depression Rating Scale, has been met according to an Otsuka Pharmaceuticals media release.
- 16 May 2011 Results have been presented at APA-2011 according to an Otsuka Pharmaceuticals media release; results were also reported in the media release.